Movement Alert｜Insmed Rises 30.27% in Regular Trading, Q2 Earnings Massively Beat Expectations with Raised Full-Year Guidance

Market Focus08-06 21:32

On August 6, Insmed surged 30.27% in regular trading, trading at $131.0/share, with turnover of $179 million. The rally was driven by the company's Q2 earnings report that comprehensively exceeded market expectations, coupled with a significant upward revision of full-year revenue guidance.

Specifically, Insmed posted a Q2 loss of just $0.06 per share, far better than the analyst consensus estimate of a $0.69-$0.73 loss, representing a beat of approximately 92% and a 96.47% improvement from the $1.70 per share loss in the year-ago period. Revenue reached $425.5 million, up from $107.4 million a year earlier and exceeding the $393 million consensus estimate by roughly 8.3%.

Additionally, the company raised its full-year Brinsupri revenue guidance to a range of $1.25 billion to $1.40 billion, up from its prior outlook of at least $1 billion, while reiterating Arikayce revenue guidance of $450 million to $470 million. The accelerating commercial uptake of Brinsupri since its approval, combined with positive clinical data from the TPIP pipeline, further validates the company's multi-product growth thesis.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147140975?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-06 21:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147140975","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Insmed Rises 30.27% in Regular Trading, Q2 Earnings Massively Beat Expectations with Raised Full-Year Guidance","media":"Market Focus","content":"<p><p>On August 6, Insmed surged 30.27% in regular trading, trading at $131.0/share, with turnover of $179 million. The rally was driven by the company's Q2 earnings report that comprehensively exceeded market expectations, coupled with a significant upward revision of full-year revenue guidance.</p><p>Specifically, Insmed posted a Q2 loss of just $0.06 per share, far better than the analyst consensus estimate of a $0.69-$0.73 loss, representing a beat of approximately 92% and a 96.47% improvement from the $1.70 per share loss in the year-ago period. Revenue reached $425.5 million, up from $107.4 million a year earlier and exceeding the $393 million consensus estimate by roughly 8.3%.</p><p>Additionally, the company raised its full-year Brinsupri revenue guidance to a range of $1.25 billion to $1.40 billion, up from its prior outlook of at least $1 billion, while reiterating Arikayce revenue guidance of $450 million to $470 million. The accelerating commercial uptake of Brinsupri since its approval, combined with positive clinical data from the TPIP pipeline, further validates the company's multi-product growth thesis.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Insmed Rises 30.27% in Regular Trading, Q2 Earnings Massively Beat Expectations with Raised Full-Year Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Insmed Rises 30.27% in Regular Trading, Q2 Earnings Massively Beat Expectations with Raised Full-Year Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-06 21:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 6, Insmed surged 30.27% in regular trading, trading at $131.0/share, with turnover of $179 million. The rally was driven by the company's Q2 earnings report that comprehensively exceeded market expectations, coupled with a significant upward revision of full-year revenue guidance.</p><p>Specifically, Insmed posted a Q2 loss of just $0.06 per share, far better than the analyst consensus estimate of a $0.69-$0.73 loss, representing a beat of approximately 92% and a 96.47% improvement from the $1.70 per share loss in the year-ago period. Revenue reached $425.5 million, up from $107.4 million a year earlier and exceeding the $393 million consensus estimate by roughly 8.3%.</p><p>Additionally, the company raised its full-year Brinsupri revenue guidance to a range of $1.25 billion to $1.40 billion, up from its prior outlook of at least $1 billion, while reiterating Arikayce revenue guidance of $450 million to $470 million. The accelerating commercial uptake of Brinsupri since its approval, combined with positive clinical data from the TPIP pipeline, further validates the company's multi-product growth thesis.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INSM","symbol_name":"Insmed","start_time":0,"source_url":"","article_id":"1147140975","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147140975","pubTimestamp":1786023150,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 6, Insmed surged 30.27% in regular trading, trading at $131.0/share, with turnover of $179 million. The rally was driven by the company's Q2 earnings report that comprehensively exceeded...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INSM":"Insmed"},"translate_title":"走势警报|Insmed 常规交易上涨 30.27%，第二季度盈利大幅超出预期，全年指引上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":1},"content_text":"On August 6, Insmed surged 30.27% in regular trading, trading at $131.0/share, with turnover of $179 million. The rally was driven by the company's Q2 earnings report that comprehensively exceeded market expectations, coupled with a significant upward revision of full-year revenue guidance.Specifically, Insmed posted a Q2 loss of just $0.06 per share, far better than the analyst consensus estimate of a $0.69-$0.73 loss, representing a beat of approximately 92% and a 96.47% improvement from the $1.70 per share loss in the year-ago period. Revenue reached $425.5 million, up from $107.4 million a year earlier and exceeding the $393 million consensus estimate by roughly 8.3%.Additionally, the company raised its full-year Brinsupri revenue guidance to a range of $1.25 billion to $1.40 billion, up from its prior outlook of at least $1 billion, while reiterating Arikayce revenue guidance of $450 million to $470 million. The accelerating commercial uptake of Brinsupri since its approval, combined with positive clinical data from the TPIP pipeline, further validates the company's multi-product growth thesis.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147140975","isCrawlerRequest":true}